Inactive Instrument

BioSante Pharmaceuticals, Inc. Stock Nasdaq

Equities

US09065V2034

Pharmaceuticals

End-of-day quote Nasdaq
- USD - Intraday chart for BioSante Pharmaceuticals, Inc.
Sales 2024 * 539M Sales 2025 * 577M Capitalization 1.26B
Net income 2024 * 33M Net income 2025 * 41M EV / Sales 2024 * 2.37 x
Net Debt 2024 * 20.98M Net cash position 2025 * 44.87M EV / Sales 2025 * 2.11 x
P/E ratio 2024 *
41.4 x
P/E ratio 2025 *
27 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 80.44%
More Fundamentals * Assessed data

Latest transcript on BioSante Pharmaceuticals, Inc.

Managers TitleAgeSince
Chief Executive Officer 46 20-09-07
Director of Finance/CFO 53 16-05-05
Chairman 63 18-05-16
Members of the board TitleAgeSince
Director/Board Member 60 18-04-30
Director/Board Member 66 20-08-05
Chairman 63 18-05-16
More insiders
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.
Related indices
More about the company